Gilead beats Street

Gilead Sciences Inc. (NASDAQ:GILD) reported 3Q10 non-GAAP diluted EPS of $0.90, beating by $0.03 the Street's $0.87 estimate and up 15% from $0.78 in 3Q09. Revenues increased 8% to $1.9 billion from $1.8 billion in 3Q09. The Street was expecting $1.9 billion in revenue. Gilead said it repurchased $1.6 billion in common stock in 3Q10.

Combined sales of Gilead's antiviral products were $1.7 billion in 3Q10, up 12% from $1.5 billion in 3Q09. Sales of HIV drug Atripla, a fixed-dose combination of HIV drug Truvada emtricitabine/tenofovir and Sustiva efavirenz from Bristol-Myers Squibb Co. (NYSE:BMY) rose 23% to $742.7 million. Truvada sales grew 8% to $668.7 million. ...